Your browser doesn't support javascript.
loading
Comparison of retinal layer thickness and microvasculature changes in patients with diabetic retinopathy treated with intravitreous bevacizumab vs panretinal photocoagulation.
Lee, Min-Woo; Baek, Seung-Kook; Lee, Kook-Hyung; Lee, Sung-Chul; Kim, Jung-Yeul; Lee, Young-Hoon.
Affiliation
  • Lee MW; Department of Ophthalmology, Konyang University Hospital, Konyang University College of Medicine, #158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.
  • Baek SK; Nuri Eye Hospital, Daejeon, Republic of Korea.
  • Lee KH; Department of Ophthalmology, Konyang University Hospital, Konyang University College of Medicine, #158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.
  • Lee SC; Department of Ophthalmology, Konyang University Hospital, Konyang University College of Medicine, #158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.
  • Kim JY; Department of Ophthalmology, Chugnam National University Hospital, Daejeon, Republic of Korea.
  • Lee YH; Department of Ophthalmology, Konyang University Hospital, Konyang University College of Medicine, #158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea. astrix001@gmail.com.
Sci Rep ; 12(1): 1570, 2022 01 28.
Article in En | MEDLINE | ID: mdl-35091585
ABSTRACT
To compare changes in retinal layers and microvasculature in diabetic retinopathy (DR) patients after bevacizumab therapy and panretinal photocoagulation (PRP). This prospective study divided patients into two groups patients treated with bevacizumab and those treated with PRP. Patients visited our retinal clinic at 1, 3, and 6 months after treatment. Retinal layer thickness and vessel density (VD) using optical coherence tomography angiography were analyzed. 37 eyes in the bevacizumab group and 36 eyes in the PRP group were enrolled. In the bevacizumab group, the parafoveal RNFL, GCL, and IPL thicknesses significantly decreased (P < 0.001, P = 0.013, and P = 0.017, respectively), whereas the thicknesses in the PRP group showed an increasing tendency over time (P = 0.087, P = 0.005, and P = 0.003, respectively). The VD of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in the bevacizumab group did not show significant changes, whereas the VD in the PRP group significantly increased over time (both P < 0.001). Additionally, RNFL (P = 0.001) and GCL thicknesses (P = 0.035) were significant factors affecting changes in BCVA, whereas the VDs of SCP and DCP did not. Patients who received bevacizumab therapy did not show a significant change in macular VD, whereas the VD of patients after PRP significantly increased after treatment. The increased macular VD in patients after PRP would be associated with the increased inner retinal layer thickness after treatment, which was significantly related to the impairment in visual acuity.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bevacizumab Type of study: Observational_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bevacizumab Type of study: Observational_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2022 Document type: Article